Key result
Aggressive hemodynamic support and oseltamivir reverse Influenza B perimyocarditis shock, restoring LVEF to ~50%.
Case Report (n=1)
Influenza B can rarely cause severe acute perimyocarditis and cardiogenic shock, which can be successfully managed with aggressive hemodynamic support and antiviral therapy.
Adds recovery case with oseltamivir in influenza B perimyocarditis shock; hypothesis-generating, needs prospective trials.
We have presented a case of 41-year-old male who presented to the hospital with worsening shortness of breath, fatigue and flu-like symptoms. On admission to hospital, the patient was in severe cardiogenic shock secondary to acute perimyocarditis. He was admitted to the cardiac intensive care unit for close monitoring and aggressive hemodynamic support. Influenza B antigen was detected in nasopharyngeal aspirate and the patient was started on oseltamivir. The patient's cardiac function improved significantly in few days and he was discharged home in stable condition with normal ejection fraction.
No takes yet. Share an insight, caveat, or question.
Hashmi et al. (2018) conducted a case report in Cardiogenic shock secondary to acute perimyocarditis (Influenza B) (n=1). Oseltamivir and aggressive hemodynamic support was evaluated on Clinical recovery and improvement in ejection fraction. A 41-year-old male with severe cardiogenic shock secondary to Influenza B perimyocarditis successfully recovered with aggressive hemodynamic support and oseltamivir, with ejection fraction improving from 16-20% to 51%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: